BY THE NUMBERS
Advances in fluorescent technology brought to light.

MediBeacon’s robust platform of agents are being designed to facilitate measurement of what was once difficult to measure. Once in the hands of physicians, the data obtained by these measurements has the potential to aid physicians in dramatically changing areas of medicine, including but not limited to helping to expedite the identification, monitoring and treatment of kidney disease and gastroenterological disorders. Additional applications target the measurement of physiology in ophthalmology, surgery and beyond. The potential impact could be on a global scale.

30+
Granted US Patents
110+
Granted Global Patents
Including Composition of Matter, Algorithm, and Method Patents
8
Fluorescent tracer agent pharmaceuticals specifically engineered for renal clearance
October 22, 2018
FDA Grants Breakthrough Device Status for MediBeacon’s Transdermal GFR Measurement System.
$1.1M

Grant from the Gates Foundation is awarded to MediBeacon in collaboration with Washington University.

30+
Peer reviewed MediBeacon publications
200+
Peer reviewed preclinical
publications and conference abstracts in which the transdermal mGFR technique has been used

Forward-Looking Statements
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.